Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy

Heba F. Taha; Lamiaa Kamel; Ahmed Embaby; Lobna A. Abdelaziz

doi:10.5114/wo.2022.115459

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2022
vol. 26

Send email

Copy url:

abstract:

Original paper

Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy

Heba F. Taha

¹

,

Lamiaa Mahmoud Kamel

²

,

Ahmed Embaby

³

,

Lobna A. Abdelaziz

⁴

Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Contemp Oncol (Pozn) 2022; 26 (1): 69–77

DOI: https://doi.org/10.5114/wo.2022.115459

Online publish date: 2022/03/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Taha H, Kamel LM, Embaby A, A. Abdelaziz L. Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy. Contemporary Oncology/Współczesna Onkologia. 2022;26(1):69-77. doi:10.5114/wo.2022.115459.

APA

Taha, H., Kamel, L. M., Embaby, A.,  & A. Abdelaziz, L. (2022). Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy. Contemporary Oncology/Współczesna Onkologia, 26(1), 69-77. https://doi.org/10.5114/wo.2022.115459

Chicago

Taha, Heba F., Lamiaa M Kamel, Ahmed Embaby,  and Lobna A. Abdelaziz. 2022. "Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy". Contemporary Oncology/Współczesna Onkologia 26 (1): 69-77. doi:10.5114/wo.2022.115459.

Harvard

Taha, H., Kamel, L., Embaby, A.,  and A. Abdelaziz, L. (2022). Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy. Contemporary Oncology/Współczesna Onkologia, 26(1), pp.69-77. https://doi.org/10.5114/wo.2022.115459

MLA

Taha, Heba F. et al. "Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy." Contemporary Oncology/Współczesna Onkologia, vol. 26, no. 1, 2022, pp. 69-77. doi:10.5114/wo.2022.115459.

Vancouver

Taha H, Kamel L, Embaby A, A. Abdelaziz L. Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy. Contemporary Oncology/Współczesna Onkologia. 2022;26(1):69-77. doi:10.5114/wo.2022.115459.

PlumX metrics:

Introduction
Despite the presence of a prognostic risk stratification sco-ring system for Hodgkin lymphoma (HL), the lymphocyte-to-monocyte ratio (LMR) is a simple and low-cost test that has been investigated as a prognostic marker to evaluate the clinical course and survival outcomes.

Material and methods
We prospectively enrolled 92 patients with classical HL (CHL), who were diagnosed and treated in the period from April 2017 to April 2020. Lymphocyte monocyte ratio cut-off values were estimated using receiver operating characteristic curves.

Results
We found that patients with LMR < 1.4 at the time of diagnosis had poorer progression-free survival (PFS) and overall survival (OS) than those with LMR > 1.4. Patients with increased LMR values after the first 2 cycles of chemotherapy had better PFS and OS; meanwhile, patients who had low LMR after the end of chemotherapy had poorer PFS and OS in comparison to patients who gained higher value after the completion of all cycles of chemotherapy.

Conclusions
A rise of LMR value indicated better outcome and better survival rate, so it can be an independent prognostic factor for survival and to predict outcome in patients with CHL.

keywords:

Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy

Heba F. Taha 1 , Lamiaa Mahmoud Kamel 2 , Ahmed Embaby 3 , Lobna A. Abdelaziz 4

Hodgkin lymphoma, LMR, prognosis, chemotherapy

Heba F. Taha

¹

,

Lamiaa Mahmoud Kamel

²

,

Ahmed Embaby

³

,

Lobna A. Abdelaziz

⁴